Ferulic acid / LDH Cancer Research Results

Bamboo shoots       243.6 mg/100g
Sugar-beet pulp     800 mg/100g
Popcorn             313 mg/100g
Wheat bran	    500–1500mg/100g
Whole wheat flour   100–300mg/100g

Pathway / Target	Modulation by FA / Direction
Aβ aggregation	         ↓ Inhibits fibril formation and destabilizes existing Aβ fibrils 
BACE‑1 & APP	         ↓ Reduces BACE-1 and APP expression; ↑ MMP‑2/‑9 expression promoting Aβ clearance
Tau hyperphosphorylation  Implicitly ↓ through modulation of Ca²⁺/CDK5/GSK3β pathways
Ca²⁺         	         ↓ FA lowers STEP levels via chelation of Ca²⁺, suppressing PP2B → restores synaptic plasticity
(AChE / BChE)	         ↓ Inhibition of AChE (FA IC₅₀~15 µM, derivatives IC₅₀ down to 0.006 µM); also BChE
(MAO‑A/B)	         ↓ Inhibits MAO‑B (derivatives IC₅₀ ~0.3–0.7 µM), reducing ROS
ROS                      ↓ Scavenges ROS, enhances antioxidant enzymes (e.g., catalase), ↓ MDA
(COX‑2, 5‑LOX, NLRP3)	 ↓ Derivatives inhibit COX‑2/5‑LOX; derivative 13a ↓ NLRP3 inflammasome
Iron/Cu²⁺ chelation	 ↓ Metal-induced Aβ aggregation via chelation by FA and derivatives
Autophagy & Aβ clearance  ↗ Suggested promotion of autophagy mechanisms targeting Aβ

Ferulic acid — Ferulic acid is a naturally occurring hydroxycinnamic phenolic acid concentrated in plant cell walls, particularly in cereal bran, whole grains, rice bran, corn, oats, wheat, bamboo shoots, and some fruits and vegetables. It is formally classified as a dietary polyphenol and phenolic antioxidant; the standard abbreviation is FA. Most food-derived FA is ester-linked to arabinoxylans, lignin, and other structural polysaccharides, whereas free FA is more readily absorbed. FA has predominantly antioxidant and cytoprotective activity in normal tissues, but can produce antiproliferative, pro-oxidant, mitochondrial, apoptotic, pyroptotic, and anti-invasive effects in susceptible cancer models. It is not an approved anticancer drug.

Primary mechanisms (ranked):

1. Induction of cancer-cell growth arrest and mitochondrial cell death through suppression of PI3K/AKT/mTOR, STAT3, cyclins, and CDKs, with activation of p53, p21, BAX, caspases, and related stress pathways.
2. Context-dependent redox disruption in cancer cells, including ROS accumulation, glutathione and antioxidant-enzyme depletion, mitochondrial dysfunction, lipid peroxidation, and ROS/JNK/BAX-dependent apoptosis or pyroptosis.
3. Suppression of EMT, migration, invasion, angiogenesis, and metastasis through modulation of MMP2, MMP9, VEGF, β-catenin/ZEB1, vimentin, E-cadherin, NF-κB, and related pathways.
4. Inhibition of glycolytic and anabolic signalling, including reductions in c-MYC, PKM2, LDH, CAIX, PI3K/AKT/mTOR, and tumor-associated glycolysis in selected models.
5. Modulation of DNA-damage responses and cell-cycle checkpoints, including ATM, ATR, CHK1/2, γH2AX, p53, p21, CDC25, CDK2, CDK4/6, and cyclin D1.
6. Suppression of tumor-promoting inflammatory signalling, particularly NF-κB, COX-2, JAK2/STAT3, inflammatory cytokines, and related mediators.
7. NRF2/HO-1 and direct radical-scavenging activity are central to normal-cell protection but are secondary and context-dependent in cancer, where antioxidant signalling could theoretically protect some tumors from oxidative therapies.

Bioavailability / PK relevance: Orally administered FA is absorbed from the stomach and small intestine, with additional release and microbial conversion of cereal-bound FA in the colon. It undergoes rapid first-pass glucuronidation, sulfation, methylation, and glycine conjugation; circulating material is predominantly conjugated rather than free FA. Food-matrix binding is a major constraint: free FA and processed or enzymatically released FA are more bioavailable than intact bran-bound FA. Human cereal studies have reported free or equivalent plasma concentrations in the low-nanomolar range, while pharmacokinetic results from herbal mixtures cannot be directly extrapolated to purified FA. Nanoencapsulation, phospholipid carriers, ester derivatives, and enzymatic liberation from bran can increase exposure experimentally, but none is established for oncology.

In-vitro vs systemic exposure relevance: Most anticancer experiments use approximately 25–500 µM FA, with many cytotoxic effects occurring at 100 µM or higher. These concentrations substantially exceed the low-nanomolar free FA levels typically observed after ordinary dietary intake and likely exceed sustained free systemic exposure achievable with conventional oral preparations. Therefore, direct systemic tumor cytotoxicity from dietary FA is pharmacokinetically implausible. Local gastrointestinal exposure, metabolites, repeated dosing, formulated delivery, or pharmacological derivatives may be more relevant than plasma free-FA concentrations.

Clinical evidence status: Cancer evidence is preclinical, consisting mainly of cultured cancer cells and rodent xenograft or carcinogenesis models. There are no established oncology RCTs showing tumor response, progression-free survival, or overall-survival benefit from purified FA. Radiosensitization and chemosensitization have been reported experimentally, but FA also protects normal tissues from radiation and chemotherapy injury; the net interaction is treatment-, timing-, dose-, and tissue-dependent. Human evidence is limited mainly to dietary bioavailability, topical dermatology, cardiovascular or metabolic observations, and combination supplements studied in cognitive impairment. FA should not be classified as a clinically validated anticancer therapy.

Ferulic Acid Mechanistic Profile

P: 0–30 min    R: 30 min–3 hr    G: >3 hr

Alzheimer’s disease relevance: Ferulic acid has substantial preclinical relevance to Alzheimer’s disease through direct inhibition of amyloid-β aggregation, attenuation of APP and BACE1 processing, reduction of tau phosphorylation, suppression of neuroinflammation and oxidative injury, metal chelation, preservation of mitochondrial function, and modulation of cholinergic signalling. FA and several FA-derived multifunctional compounds inhibit AChE or BChE in vitro, but the potency of derivatives should not be attributed to unmodified FA. Small human studies have evaluated combination products containing FA and Angelica archangelica extract in mild cognitive impairment or dementia-related symptoms; these do not establish efficacy of isolated FA or demonstrate disease modification. The clinical evidence remains preliminary and formulation-specific.

AD clinical evidence status: Strong preclinical evidence; limited small human combination-product studies; no confirmatory phase III trial; no regulatory approval for prevention or treatment of Alzheimer’s disease. Reported cognitive findings require replication using isolated FA, adequate sample sizes, biomarker-defined populations, validated dosing, and longer follow-up.

Ferulic Acid in Alzheimer’s Disease

P: 0–30 min    R: 30 min–3 hr    G: >3 hr